Literature DB >> 7538981

Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.

M Lekili1, M Zengin, H Postaci, A R Ayder.   

Abstract

Prostate specific antigen (PSA) is the most important tumour marker which, used routinely, proved to have a positive correlation with tumour volume and pathological stage. To evaluate the relationship between serum PSA and histologic grading of prostatic carcinoma, preoperative PSA determinations were made in 25 patients with prostatic cancer. Biopsy materials were evaluated and the Gleason scores were adjusted for histologic grading. The higher values of PSA were proportional to the Gleason scores of the primary prostatic biopsy.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7538981     DOI： 10.1007/bf02767722

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  10 in total

1.  Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase.

Authors:  H Svanholm
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1986-01

Review 2.  What's new in tumor markers for prostate cancer?

Authors:  T M Chu; G P Murphy
Journal:  Urology       Date:  1986-06       Impact factor: 2.649

3.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

4.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.

Authors:  T A Stamey; J N Kabalin
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

5.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

Authors:  T A Stamey; J N Kabalin; J E McNeal; I M Johnstone; F Freiha; E A Redwine; N Yang
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

6.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

Authors:  A W Partin; H B Carter; D W Chan; J I Epstein; J E Oesterling; R C Rock; J P Weber; P C Walsh
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

7.  The proteolytic activity of human prostate-specific antigen.

Authors:  Y Ban; M C Wang; K W Watt; R Loor; T M Chu
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

8.  Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.

Authors:  D W Ellis; S Leffers; J S Davies; A B Ng
Journal:  Am J Clin Pathol       Date:  1984-03       Impact factor: 2.493

9.  Use of human prostate-specific antigen in monitoring prostate cancer.

Authors:  M Kuriyama; M C Wang; C I Lee; L D Papsidero; C S Killian; H Inaji; N H Slack; T Nishiura; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1981-10       Impact factor: 12.701

10.  Immunoperoxidase localization of prostate-specific antigen.

Authors:  B S Stein; S Vangore; R O Petersen; A R Kendall
Journal:  Am J Surg Pathol       Date:  1982-09       Impact factor: 6.394
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.